CD163 and macrophage activation syndrome: In 2018, Sakumura et al., studying 63 patients with sJIA, concluded that sCD163 is a potential biomarker for the evaluation of disease activity and remission, faithfully reflecting macrophage activation in sJIA—even for patients treated with TCZ; its levels increased dramatically with the progression of MAS in sJIA [150].